Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SJX 653

Next Previous
Drug Profile

SJX 653

Alternative Names: SJX-653

Latest Information Update: 28 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Sojournix
  • Class Small molecules
  • Mechanism of Action Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hot flashes

Most Recent Events

  • 28 Feb 2022 No recent reports of development identified for phase-I development in Hot-flashes in USA (PO, Tablet)
  • 15 Mar 2021 Sojournix terminates phase II trial in Hot flashes in Germany, Belgium, Poland and UK (NCT04278872)
  • 09 Nov 2020 Sojournix reinitiates a phase II trial for Hot flashes in United Kingdom, Poland, Germany and Spain (PO) (NCT04278872)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top